Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data Evelien Roekevisch, MD, Mandy Elvira Schram, MD, PhD, Mariska Maria Geertruida Leeflang, PhD, Marijke Willemijn Dorothée Brouwer, MD, Louise Anna Andrea Gerbens, MD, Jan Dositheus Bos, MD, PhD, FRCP, MPH, Phyllis Ira Spuls, MD, PhD Journal of Allergy and Clinical Immunology Volume 141, Issue 2, Pages 825-827.e10 (February 2018) DOI: 10.1016/j.jaci.2017.09.033 Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig E1 Flowchart. *Three patients stopped treatment with AZA because of controlled AD, but restarted AZA after 6 to 9 months because of a relapse. Journal of Allergy and Clinical Immunology 2018 141, 825-827.e10DOI: (10.1016/j.jaci.2017.09.033) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig E2 A, Mean (SD) total SCORAD index scores at baseline, 3 months, and 24 months (2 years) (ITT analysis). B, Mean (SD) total SCORAD index scores at baseline, 3 months and 24 months (2 years) (PP analysis). Journal of Allergy and Clinical Immunology 2018 141, 825-827.e10DOI: (10.1016/j.jaci.2017.09.033) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig E3 A, Mean (SD) SCORAD index scores up to 2 years after baseline in patients with and without a filaggrin mutation (ITT analysis). B, Mean (SD) SCORAD index scores up to 2 years after baseline in patients with and without a filaggrin mutation (PP analysis). Journal of Allergy and Clinical Immunology 2018 141, 825-827.e10DOI: (10.1016/j.jaci.2017.09.033) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions